Jie Liang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5646640/publications.pdf

Version: 2024-02-01



LE LIANC

#	Article	IF	CITATIONS
1	Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. The Lancet Gastroenterology and Hepatology, 2020, 5, 667-678.	8.1	804
2	Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice. Journal of Hepatology, 2018, 68, 773-782.	3.7	276
3	Implications of COVID-19 for patients with pre-existing digestive diseases. The Lancet Gastroenterology and Hepatology, 2020, 5, 425-427.	8.1	274
4	Downregulation of gasdermin D promotes gastric cancer proliferation by regulating cell cycleâ€related proteins. Journal of Digestive Diseases, 2018, 19, 74-83.	1.5	142
5	HMGA2–FOXL2 Axis Regulates Metastases and Epithelial-to-Mesenchymal Transition of Chemoresistant Gastric Cancer. Clinical Cancer Research, 2017, 23, 3461-3473.	7.0	118
6	O-GlcNAcylation promotes colorectal cancer metastasis via the miR-101-O-GlcNAc/EZH2 regulatory feedback circuit. Oncogene, 2019, 38, 301-316.	5.9	93
7	Intraperitoneal injection (IP), Intravenous injection (IV) or anal injection (AI)? Best way for mesenchymal stem cells transplantation for colitis. Scientific Reports, 2016, 6, 30696.	3.3	90
8	Cellular prion protein promotes proliferation and G1/S transition of human gastric cancer cells SGC7901 and AGS. FASEB Journal, 2007, 21, 2247-2256.	0.5	82
9	Fatty acid-induced CD36 expression via O-GlcNAcylation drives gastric cancer metastasis. Theranostics, 2019, 9, 5359-5373.	10.0	82
10	The miR27b-CCNG1-P53-miR-508-5p axis regulates multidrug resistance of gastric cancer. Oncotarget, 2016, 7, 538-549.	1.8	68
11	QingBai decoction regulates intestinal permeability of dextran sulphate sodiumâ€induced colitis through the modulation of notch and NFâ€̂PB signalling. Cell Proliferation, 2019, 52, e12547.	5.3	67
12	Involvement of digestive system in COVID-19: manifestations, pathology, management and challenges. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482093462.	3.2	48
13	miR-148b-3p inhibits gastric cancer metastasis by inhibiting the Dock6/Rac1/Cdc42 axis. Journal of Experimental and Clinical Cancer Research, 2018, 37, 71.	8.6	46
14	Inhibition of PI3K/Akt partially leads to the inhibition of PrP ^C â€induced drug resistance in gastric cancer cells. FEBS Journal, 2009, 276, 685-694.	4.7	45
15	Elevated O-GlcNAcylation promotes gastric cancer cells proliferation by modulating cell cycle related proteins and ERK 1/2 signaling. Oncotarget, 2016, 7, 61390-61402.	1.8	39
16	Hypoxia induced overexpression of PrPC in gastric cancer cell lines. Cancer Biology and Therapy, 2007, 6, 769-774.	3.4	33
17	FOXK1 plays an oncogenic role in the development of esophageal cancer. Biochemical and Biophysical Research Communications, 2017, 494, 88-94.	2.1	33
18	O-GlcNAcylation of SIX1 enhances its stability and promotes Hepatocellular Carcinoma Proliferation. Theranostics, 2020, 10, 9830-9842.	10.0	33

Jie Liang

#	Article	IF	CITATIONS
19	Role of the intestinal microbiota and fecal transplantation in inflammatory bowel diseases. Journal of Digestive Diseases, 2014, 15, 641-646.	1.5	27
20	Differential expression of calcium-related genes in gastric cancer cells transfected with cellular prion protein. Biochemistry and Cell Biology, 2007, 85, 375-383.	2.0	25
21	Coronin3 regulates gastric cancer invasion and metastasis by interacting with Arp2. Cancer Biology and Therapy, 2014, 15, 1163-1173.	3.4	19
22	Factor V Leiden and inflammatory bowel disease: a systematic review and meta-analysis. Journal of Gastroenterology, 2011, 46, 1158-1166.	5.1	16
23	Specific changes of enteric mycobiota and virome in inflammatory bowel disease. Journal of Digestive Diseases, 2018, 19, 2-7.	1.5	14
24	MGr1-Antigen/37 kDa laminin receptor precursor promotes cellular prion protein induced multi-drug-resistance of gastric cancer. Oncotarget, 2017, 8, 71630-71641.	1.8	14
25	Function of PrP ^C (1â€OPRD) in biological activities of gastric cancer cell lines. Journal of Cellular and Molecular Medicine, 2009, 13, 4453-4464.	3.6	13
26	Responding to COVID-19: Perspectives From the Chinese Society of Gastroenterology. Gastroenterology, 2020, 158, 2024-2027.	1.3	13
27	Enah overexpression is correlated with poor survival and aggressive phenotype in gastric cancer. Cell Death and Disease, 2018, 9, 998.	6.3	12
28	Sec62 promotes gastric cancer metastasis through mediating UPR-induced autophagy activation. Cellular and Molecular Life Sciences, 2022, 79, 133.	5.4	11
29	GX1 targeting delivery of rmhTNFα evaluated using multimodality imaging. International Journal of Pharmaceutics, 2014, 461, 181-191.	5.2	10
30	Increased expression of calponin 2 is a positive prognostic factor in pancreatic ductal adenocarcinoma. Oncotarget, 2017, 8, 56428-56442.	1.8	10
31	Comparison of the efficiency of different enemas on patients with distal ulcerative colitis. Cell Proliferation, 2019, 52, e12559.	5.3	7
32	Assessment of patient-centered outcomes (PROs) in inflammatory bowel disease (IBD): a multicenter survey preceding a cross-disciplinary (functional) consensus. Health and Quality of Life Outcomes, 2020, 18, 241.	2.4	5
33	Real-world Short-term Effectiveness of Ustekinumab in Crohn's Disease: Results from a Multicenter, Prospective Study in China. Inflammatory Bowel Diseases, 2022, 28, S42-S44.	1.9	5
34	Systematic review with metaâ€analysis: incidence and factors for progression to advanced neoplasia in inflammatory bowel disease patients with indefinite and lowâ€grade dysplasia. Alimentary Pharmacology and Therapeutics, 2022, 55, 632-644.	3.7	4
35	Aplastic anemia associated with Crohn's disease: a tertiary center retrospective study. Annals of Hematology, 2019, 98, 2053-2061.	1.8	3
36	5-Aminosalicylic Acid Prevents Disease Behavior Progression and Intestinal Resection in Colonic and Ileocolonic Crohn's Disease Patients: A Retrospective Study. Canadian Journal of Gastroenterology and Hepatology, 2021, 2021, 1-8.	1.9	2

#	Article	IF	CITATIONS
37	Secondary Indicators for an Evaluation and Guidance System for Quality of Care in Inflammatory Bowel Disease Centers: A Critical Review of the Inflammatory Bowel Disease Quality of Care Center. Inflammatory Bowel Diseases, 2022, 28, S3-S8.	1.9	2

Jie Liang